REGULATORY

MHLW OKs Add’l Indications for Keytruda, Tecentriq, Hemlibra, and More

December 25, 2018
The Ministry of Health, Labor and Welfare (MHLW) on December 21 approved new key indications for MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) and Chugai Pharmaceutical’s anti-PD-L1 antibody Tecentriq (atezolizumab) and hemophilia treatment Hemlibra (emicizumab). Keytruda earned a string of label expansions…

To read the full story

Related Article

REGULATORY

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Rejii Anasako

While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…